Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis.

In a major breakthrough for haemophilia care, the National Institute for Health and Care Excellence (NICE) has issued final draf ...

In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for migaldendranib for the treatment of ...

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

Biocon Biologics and Yoshindo expand access to ustekinumab biosimilar in Japan: Our Bureau, Bengaluru Wednesday, May 21, 2025, 15:15 Hrs [IST] Biocon Biologics a fully integrated ...

Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA).

A domestic study has demonstrated the effect of deoxycholic acid (DCA), the main component of fat-destroying injections, on ...